GSK plans $800M expansion of Pennsylvania drug manufacturing facilities

 By John George – Senior Reporter, Philadelphia Business Journal

GSK, the London-based Big Pharma company that has operations in Philadelphia and Montgomery County, said Thursday it plans to invest up to $800 million to expand its manufacturing operations in Pennsylvania.

The company said the spending on a new "multi-purpose facility" at its campus in Marietta, Lancaster County, represents its largest-ever U.S. manufacturing investment. The project is expected to create 200 new jobs.

Pennsylvania is investing $21 million in the project, making it the largest state-supported economic development project in the history of Lancaster County. The state funding package includes $18 million in a Redevelopment Assistance Capital Program (RACP) grants, a $2.35 million Pennsylvania First grant, and a $645,000 WEDnet grant to train employees.

Rick Siger, secretary of the Pennsylvania Department of Community and Economic Development, said the GSK project is an example of the state's focus on growing the life sciences industry under Gov. Josh Shapiro's 10-year economic development strategy.

"The Commonwealth is home to nearly 3,100 life sciences firms," Siger said in a statement. "We will continue to make bold investments like this one to further boost the industry."

GSK (NYSE: GSK) said a new 300,000-square-foot plant will be designed to manufacture sterile liquid vaccines and medicines, and will also house a research and development pilot plant to manufacture medicines for clinical trials.

Additionally, GSK plans to establish a new vaccines drug substance plant at the site, dedicated to manufacturing products based on the company’s novel MAPS (multiple antigen presenting system) technology, subsequent to future regulatory submissions and approvals.

The project will also involve renovating existing buildings on the Marietta campus at 325 North Bridge St.

"This landmark investment will establish Marietta as an innovation and manufacturing hub capable of delivering next generation medicines and vaccines to people around the world," said Regis Simard, GSK's president for global supply chain, in a statement.

Full story: https://tinyurl.com/42y9jn3n

www.omegare.com